Currently held
- Agent 20 — SIR Price/Volumelong5 sh @ $360.25 · stop $335.80+$51.95 unrealized
LH
Laboratory Corp Of America HoldingsHealth Careinsider_universeLast close $370.48Nov 12, 2026
Day −0.49%
Everything we've seen
- ·Nov 15, 11:31 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 11:31 AMstreamnews
Labcorp’s Lab Growth Surges as $125 Million Reimbursement Risk Looms
Labcorp (NYSE:LH) Chief Financial Officer Julia Wang said strength in the company’s central laboratory business and diagnostic testing helped drive third-quarter growth, while management prepares for a potential reduction in government reimbursement rates in 2027. Speaking at the UBS Global Healthc
- ·Nov 15, 11:16 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 11:16 AMstreamnews
Labcorp’s Lab Growth Surges as $125 Million Reimbursement Risk Looms
Labcorp (NYSE:LH) Chief Financial Officer Julia Wang said strength in the company’s central laboratory business and diagnostic testing helped drive third-quarter growth, while management prepares for a potential reduction in government reimbursement rates in 2027. Speaking at the UBS Global Healthc
- ·Nov 15, 11:01 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 10:46 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 10:31 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 10:16 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 10:01 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 9:46 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 9:31 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 9:16 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 9:01 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 8:46 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 8:31 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 8:16 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 8:02 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 7:46 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 7:31 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 7:16 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 7:01 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 6:46 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 6:31 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 6:16 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 6:02 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ·Nov 15, 5:46 AMstreamnews
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ❖Nov 14, 9:11 AMnewsvia finnhub
Labcorp (LH) Stock Sees Fair Value Lift After Q3 Analyst Target Increases
Labcorp Holdings is back in focus after analysts lifted fair value estimates from about US$354.50 to roughly US$390.06, a change of around 10% in updated models. Recent Q3 2026 results and guidance, plus M&A activity and product updates, sit behind a wave of refreshed research that includes new price targets and mixed ratings across the Street. As you read on, you will see how this evolving analyst narrative may shape the way you track Labcorp from here. Analyst Price Targets don't always...
- ❖Nov 14, 6:10 AMnewsvia finnhub
Labcorp (LH) Stock Looks About Right After Its Recent Run
Labcorp Holdings has delivered a strong share price run in recent years, which naturally raises a sharper question for you as an investor. Is the current price tag on the stock still grounded in the earnings power the business is generating today? Over the past 3 years the stock has returned 80.6%, which puts a lot of weight on whether that climb is backed by the underlying profit stream. Labcorp’s US$375m purchase of Millennium Health may support expectations for future earnings by...
- ❖Nov 14, 4:10 AMnewsvia finnhub
Is Labcorp Holdings (LH) Still Cheap Following Its UBS Healthcare Conference Appearance?
Labcorp Holdings (LH) is set to present at the 2026 UBS Global Healthcare Conference on November 10 in Palm Beach Gardens, Florida, providing investors with fresh commentary from Executive VP and CFO Julia A. Wang. For context, Labcorp Holdings’ share price has climbed 16.8% over the past month and 47.2% year to date, while total shareholder return over three years sits at 80.6%, suggesting momentum has been building ahead of this conference appearance. Scan beyond Labcorp Holdings and see...
- ❖Nov 13, 3:23 PMnewsvia finnhub
Should Hims & Hers Stock's Drop After Earnings Worry You?
For questions about this article or underlying research, email help@trefis.com.
- ❖Nov 13, 12:25 PMnewsvia finnhub
Should Labcorp Stock Holders Look At Quest Diagnostics Instead?
For questions about this article or underlying research, email help@trefis.com.
- ❖Nov 13, 11:14 AMnewsvia finnhub
Labcorp’s Lab Growth Surges as $125 Million Reimbursement Risk Looms
Labcorp (NYSE:LH) Chief Financial Officer Julia Wang said strength in the company’s central laboratory business and diagnostic testing helped drive third-quarter growth, while management prepares for a potential reduction in government reimbursement rates in 2027. Speaking at the UBS Global Healthc
- ❖Nov 12, 7:41 PMnewsvia finnhub
Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
- ❖Nov 12, 12:44 PMnewsvia finnhub
Who Is Paying For GeneDx's Cash Burn?
For questions about this article or underlying research, email help@trefis.com.
- ❖Nov 12, 10:13 AMnewsvia finnhub
Which Dates Could Move Hims & Hers Stock Most?
For questions about this article or underlying research, email help@trefis.com.
- ❖Nov 11, 12:41 PMnewsvia finnhub
What Happened To People Who Bought Quest Stock At A High?
For questions about this article or underlying research, email help@trefis.com.
- ❖Nov 10, 8:30 PMnewsvia finnhub
Labcorp Holdings Inc. (LH) Presents at 2026 UBS Global Healthcare Conference Transcript
Labcorp Holdings Inc. (LH) 2026 UBS Global Healthcare Conference November 10, 2026 8:44 AM ESTCompany ParticipantsJulia Wang - Executive VP &...
- ❖Nov 10, 12:57 PMnewsvia finnhub
Is Now the Right Time to Hold Labcorp Stock in Your Portfolio?
LH's specialty testing growth, AI-driven efficiencies and expanding margins support its outlook, though currency pressures and competition pose risks.
- ?Nov 10, 10:46 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
LH is down 2.05% intraday with no headline catalyst visible, suggesting this is likely flow-driven or sector/macro pressure. The macro context shows the fed funds rate printing 2 standard deviations above its 24-month trend, which creates a modestly negative backdrop for rate-sensitive healthcare services names like LabCorp — higher discount rates compress multiples and weigh on capital-intensive diagnostics businesses. With 300 minutes remaining (effectively a full afternoon session), there is ample time for the move to extend. However, the absence of a clear news driver introduces uncertainty about whether this is a one-time institutional transaction that has already exhausted itself or persistent selling pressure. The move is meaningful at ~2% but sits at the lower boundary of the 2-5% 'conviction' range, so it carries some weight but is not overwhelming. No reversal signals are explicitly present. On balance, modest continuation probability slightly above the 0.5 threshold — the macro headwind and time remaining support a continuation lean, but confidence is limited without volume confirmation or a clear catalyst.
- !Nov 10, 10:46 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
LH is down 2.05% intraday with no headline catalyst visible, suggesting this is likely flow-driven or sector/macro pressure. The macro context shows the fed funds rate printing 2 standard deviations above its 24-month trend, which creates a modestly negative backdrop for rate-sensitive healthcare services names like LabCorp — higher discount rates compress multiples and weigh on capital-intensive diagnostics businesses. With 300 minutes remaining (effectively a full afternoon session), there is ample time for the move to extend. However, the absence of a clear news driver introduces uncertainty about whether this is a one-time institutional transaction that has already exhausted itself or persistent selling pressure. The move is meaningful at ~2% but sits at the lower boundary of the 2-5% 'conviction' range, so it carries some weight but is not overwhelming. No reversal signals are explicitly present. On balance, modest continuation probability slightly above the 0.5 threshold — the macro headwind and time remaining support a continuation lean, but confidence is limited without volume confirmation or a clear catalyst.
- ❖Nov 9, 1:47 PMnewsvia finnhub
Here’s Why Wall Street Still Sees Room in Labcorp (LH) Even After Its Run
We just published a list of the 10 Best All-Time High Stocks to Buy According to Wall Street and Labcorp (NYSE:LH) ranked 10th on this list. Wall Street’s leadership changed hands over the past month. The technology and chip stocks that carried the market through most of 2026 lost ground, while healthcare, financials, real estate, […]
- ❖Nov 9, 1:00 PMnewsvia finnhub
Labcorp completes $375M Millennium Health takeover
The deal, which includes a $245 million upfront fee, expands the geographic reach of Labcorp’s drug testing business.
- ❖Nov 9, 9:08 AMnewsvia finnhub
Global Cardiovascular Genetic Testing Market Report 2026 | Capitalize on 11% CAGR and AI Genomics with Labcorp, Quest Diagnostics, Illumina, and Fulgent Genetics
Boost ROI with patient-specific clinician-ordered tests, AI analytics, multigene panels, and localized reagents and sequencing to reduce costs and offset tariffs.Dublin, Nov. 09, 2026 (GLOBE NEWSWIRE) -- "Cardiovascular Genetic Testing Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global cardiovascular genetic testing market is experiencing rapid growth as healthcare systems increase their focus on inherited cardiovascular disorders, preventive care and precision m
- ?Nov 5, 1:01 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
LH is down 1.66% today, a moderate but not outsized intraday move. The headline from today references a broad analyst note covering many tickers (Block, Cisco, Dollar Tree, etc.) with no specific mention of LH, so no catalytic news is identifiable as a driver. The macro context shows the fed funds rate printing 2.1σ above its 24-month trend, which is modestly risk-off and could weigh on healthcare/diagnostics names like LH at the margin, but LH is not a primary rate-sensitive sector. With 165 minutes remaining there is ample time for the move to continue or reverse. The move is real but not dramatic enough to signal strong institutional conviction on its own. No reversal signals are evident, but equally no clear continuation pressure is identifiable beyond the existing momentum. Given the asymmetric risk/reward of the system (tight stop, fixed target, forced flatten) and no strong countervailing reason to fade, a neutral-to-slight continuation read is warranted, landing at the minimum threshold.
- !Nov 5, 1:01 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
LH is down 1.66% today, a moderate but not outsized intraday move. The headline from today references a broad analyst note covering many tickers (Block, Cisco, Dollar Tree, etc.) with no specific mention of LH, so no catalytic news is identifiable as a driver. The macro context shows the fed funds rate printing 2.1σ above its 24-month trend, which is modestly risk-off and could weigh on healthcare/diagnostics names like LH at the margin, but LH is not a primary rate-sensitive sector. With 165 minutes remaining there is ample time for the move to continue or reverse. The move is real but not dramatic enough to signal strong institutional conviction on its own. No reversal signals are evident, but equally no clear continuation pressure is identifiable beyond the existing momentum. Given the asymmetric risk/reward of the system (tight stop, fixed target, forced flatten) and no strong countervailing reason to fade, a neutral-to-slight continuation read is warranted, landing at the minimum threshold.
- ❖Nov 5, 7:59 AMnewsvia finnhub
Buy, Sell, or Hold? Thursday’s Top Upgrades and Downgrades: Block, Cisco Systems, Dollar Tree, First Solar, HubSpot, JetBlue Airways, Nike, Space-X, Skyworks Solutions, and More
Stocks surged after a political shake-up, but Wall Street analysts were far from unanimous on Thursday. Some household names got slashed while a struggling airline and a solar giant won new fans. Which side of the call are you on?
- ❖Nov 4, 6:14 PMnewsvia finnhub
Myriad Genetics Q3 Earnings Call Highlights
Myriad Genetics (NASDAQ:MYGN) reported third-quarter revenue of $202.7 million, down 1% from a year earlier, as growth in cancer and mental health testing was offset by a decline in its prenatal business. The company raised its full-year revenue outlook and said early efforts to address reimbursemen
- ❖Nov 4, 8:00 AMnewsvia finnhub
Labcorp to Speak at the UBS Global Healthcare Conference
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Conference on November 10 at 8:45 a.m. ET.
- ❖Nov 3, 7:18 AMnewsvia finnhub
What Just Happened To Natera Stock?
For questions about this article or underlying research, email help@trefis.com.
- ❖Nov 2, 4:17 PMnewsvia finnhub
Labcorp’s Q3 earnings call: our top 5 analyst questions
Labcorp’s third quarter results were marked by strong growth in specialty testing and continued expansion in biopharma laboratory services, leading to performance that exceeded Wall Street’s expectations. Management highlighted disciplined execution and volume growth across diagnostics as key contributors. CEO Adam Schechter attributed the quarter's momentum to “continued strength in central laboratories and specialty testing,” underscoring the value of Labcorp’s clinical partnerships and recent
- ❖Nov 2, 11:30 AMnewsvia finnhub
Can Hims & Hers Stock Rally 50% After This Dip?
For questions about this article or underlying research, email help@trefis.com.
- ?Oct 30, 1:40 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
LH is down 2.10% today, a meaningful move suggesting real selling pressure. The single headline referencing 'profitable stocks with warning signs' is mildly negative in tone and may have contributed to or reinforced selling. Macro context (elevated mortgage rates) is not directly reactive to LH as a lab/diagnostics company, so macro provides little tailwind or headwind here. With 125 minutes remaining there is adequate time for continuation into the close, though the move is already mature at -2.10% which reduces the remaining downside runway before hitting natural support. No strong reversal signals are evident from the data provided. On balance, momentum favors modest continuation of the downside, but conviction is limited given the absence of a clear catalyst specific to LH and the fact that the move may already reflect most of the day's news flow. Assigning a slight lean toward continuation at 0.52.
- !Oct 30, 1:40 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
LH is down 2.10% today, a meaningful move suggesting real selling pressure. The single headline referencing 'profitable stocks with warning signs' is mildly negative in tone and may have contributed to or reinforced selling. Macro context (elevated mortgage rates) is not directly reactive to LH as a lab/diagnostics company, so macro provides little tailwind or headwind here. With 125 minutes remaining there is adequate time for continuation into the close, though the move is already mature at -2.10% which reduces the remaining downside runway before hitting natural support. No strong reversal signals are evident from the data provided. On balance, momentum favors modest continuation of the downside, but conviction is limited given the absence of a clear catalyst specific to LH and the fact that the move may already reflect most of the day's news flow. Assigning a slight lean toward continuation at 0.52.
- ❖Oct 30, 10:51 AMnewsvia finnhub
3 profitable stocks with warning signs
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
- ❖Oct 30, 3:09 AMnewsvia finnhub
Charles River (CRL) Stock Could Be 27% Overvalued As Preclinical FDA Collaboration Starts
Charles River Laboratories International has become a talking point after a sharp multi‑year rally, which naturally raises a harder question for you as an investor: Is the current share price still grounded in the cash flows the business can generate, or has enthusiasm run ahead of what those cash streams can reasonably support? Over the past 3 years the stock has returned 115.3%, which puts real pressure on the idea that the present valuation is still aligned with what the underlying cash...
- ❖Oct 30, 2:14 AMnewsvia finnhub
Labcorp (LH) Stock Fair Value Edges Higher After Q3 Analyst Revisions
The fair value estimate for Labcorp Holdings has been adjusted from US$344.25 to US$354.50, a move of about US$10.25 that reflects updated analyst work after the latest Q3 review. External analysts have gone further, with several price targets now between US$380 and US$410, which shows a wider debate around how much upside Labcorp Holdings might support if current assumptions hold. In the sections that follow, you will see how to interpret these shifting targets and track the evolving story...
- ❖Oct 29, 4:09 PMnewsvia finnhub
Labcorp Holdings (LH) Expands HPV Testing While Teaming With Regulators On Drug Safety
Labcorp Holdings (NYSE: LH) partnered with Waters Corporation to deploy the BD Onclarity HPV Assay across its national laboratory network. The BD Onclarity HPV Assay rollout is designed to broaden access to advanced cervical cancer screening for patients across the United States. Labcorp announced a collaboration with the FDA and Charles River Laboratories to refine methods used to evaluate drug abuse potential. These moves on BD Onclarity HPV testing and drug abuse potential assessment only...
- ❖Oct 29, 2:12 PMnewsvia finnhub
Labcorp (LH) Stock Shrugs Off Q3 Earnings As PAMA Risk Looms
Labcorp stock barely flinched after its Q3 2026 release, ticking around 0.6% higher near US$362 even as the company posted a muscular quarter. Revenue reached about US$3.8b and adjusted earnings per share jumped to US$4.78, with free cash flow of US$412m giving the testing giant more financial firepower. In the short term, that muted share move might look like a yawn. Over a multi-year lens, investors are weighing improving margins and a premium P/E against a leveraged balance sheet and...
- ❖Oct 29, 9:55 AMnewsvia finnhub
UBS Maintains Buy on Labcorp Holdings, Raises Price Target to $420
UBS analyst Kevin Caliendo maintains Labcorp Holdings (NYSE:LH) with a Buy and raises the price target from $380 to $420.
- ❖Oct 29, 7:14 AMnewsvia finnhub
Barclays Maintains Equal-Weight on Labcorp Holdings, Raises Price Target to $380
Barclays analyst Luke Sergott maintains Labcorp Holdings (NYSE:LH) with a Equal-Weight and raises the price target from $330 to $380.
- ❖Oct 29, 7:09 AMnewsvia finnhub
Truist Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $395
Truist Securities analyst David Macdonald maintains Labcorp Holdings (NYSE:LH) with a Buy and raises the price target from $365 to $395.
- ❖Oct 29, 4:15 AMnewsvia finnhub
Labcorp Holdings: The Optimism May Be Going Overboard (Rating Downgrade)
Labcorp Holdings raised guidance and shares surged, but valuation looks stretched. Read more on LH stock here.
- ❖Oct 29, 3:40 AMnewsvia finnhub
Baird Maintains Outperform on Labcorp Holdings, Raises Price Target to $396
Baird analyst Eric Coldwell maintains Labcorp Holdings (NYSE:LH) with a Outperform and raises the price target from $361 to $396.
- ❖Oct 28, 9:58 PMnewsvia finnhub
Labcorp (LH) stock trades up, here is why
Shares of healthcare diagnostics company Labcorp Holdings (NYSE:LH) jumped 10.3% in the afternoon session after the company reported third-quarter financial results that were above Wall Street expectations and raised its full-year forecast.
- ❖Oct 28, 8:45 PMnewsvia finnhub
Labcorp Holdings Inc. 2026 Q3 - Results - Earnings Call Presentation
2026-10-29. The following slide deck was published by Labcorp Holdings Inc.
- ▣Oct 28, 8:00 PMjournaltarget
Agent 4 — Dip Buyer (Frozen) closed long 3 @ $360.25 (+$168.81)
Target hit: close $360.25 ≥ target $341.80
- ✓Oct 28, 6:21 PMdecisionacted
Agent 20 — SIR Price/Volume — buy
[cluster_break_up] For 19 sessions from 2026-10-01 through 2026-10-27, LH traded in a tight $304.60–$331.17 band on routine volume ranging from 405K to 988K shares (20-day ADV ~646K), forming a dense price-volume cluster in 2-D space. On 2026-10-28, the close of $360.25 (+8.78%) broke decisively above that cluster on 1.8M shares — a volume z-score of 8.00 and nearly 2.8× the trailing ADV — the textbook SIR cluster_break_up signature of fresh demand absorbing the float. Importantly, the 19-day path leading into today was itself subtly constructive: up-day volume consistently dominated down-day volume (e.g., 988K on the UP day of 10/06, 962K on 10/22's UP day) while the heaviest down-day volumes remained modest (706K on 10/16, 608K on 10/09), suggesting quiet accumulation before the break. Risks: This is a single-bar event, and the SIR methodology rewards multi-session confirmation — if the next 1–3 sessions fail to hold above the prior cluster ceiling (~$331) on above-average volume, the break could prove a one-day gap/fade rather than a genuine demand surge. Additionally, the T10Y2Y at 0.29 (1.7σ below trend) signals a flattening yield curve that historically weighs on economically sensitive Health Care sub-sectors; a macro reversal or earnings-driven gap fill would invalidate the bullish read.
- ❖Oct 28, 4:59 PMnewsvia finnhub
Stock Market Today: Dow, Nasdaq Rise After No Fed Rate Hike; Labcorp Blasts Off
The Dow Jones index trimmed its gain Wednesday after the Fed held its key interest rate steady. Robinhood slid on earnings.
- ❖Oct 28, 4:06 PMnewsvia finnhub
S&P 500 Top Movers: Gainers and Losers in Today's US Session
S&P 500 top movers in today's US session: Vertiv, Flex and Oracle led gainers, while F5, CoStar and C.H. Robinson led decliners.
- ❖Oct 28, 2:37 PMnewsvia finnhub
Labcorp: Q3 Earnings Snapshot
(LH) on Wednesday reported third-quarter earnings of $262.The Burlington, North Carolina-based company said it had profit of $3.
- ❖Oct 28, 1:58 PMnewsvia finnhub
Labcorp (LH) Q3 2026 Earnings Call Transcript
Revenue grew 6.9% while operating margins expanded for a sixth consecutive quarter.
- ❖Oct 28, 1:56 PMnewsvia finnhub
LH Stock Hits Record Levels, CHE Stock Surges To Over 52-Week Highs – Here’s What’s Driving Investor Enthusiasm
Labcorp raised its FY2026 revenue and earnings forecasts following a Q3 beat, while Chemed attracted an analyst upgrade after its VITAS business drove Q3 earnings growth.
- ❖Oct 28, 1:46 PMnewsvia finnhub
Labcorp Holdings Inc. Q3 2026 Earnings Call Summary
Moby summary of Labcorp Holdings Inc.'s Q3 2026 earnings call
- ❖Oct 28, 1:36 PMnewsvia finnhub
S&P 500 Top Movers: October 28 Gainers and Losers
S&P 500 top movers for October 28: Vertiv led gainers at 13.92%, while F5 led losers at 20.64%.
- ❖Oct 28, 1:04 PMnewsvia finnhub
Labcorp Q3 Earnings Call Highlights
Labcorp (NYSE:LH) reported third-quarter 2026 revenue growth, margin expansion and double-digit adjusted earnings-per-share growth, prompting the laboratory services company to raise the midpoint of its full-year revenue and earnings outlook. Revenue rose 7% to $3.8 billion in the quarter, while ad
- ❖Oct 28, 11:36 AMnewsvia finnhub
S&P 500 Gap Movers: Oct. 28 Session
S&P 500 gap-up and gap-down stocks on Oct. 28 include Vertiv, Labcorp, F5, CoStar, and others, with several moves tied to quarterly updates.
- ❖Oct 28, 11:22 AMnewsvia finnhub
Labcorp Shares Rise 1.5% as Q3 Earnings Beat Forecasts and Full-Year Guidance Increases
Labcorp Holdings Inc. (NYSE:LH) shares advanced 1.
- ❖Oct 28, 10:52 AMnewsvia finnhub
Labcorp Holdings Inc. Reports Third Quarter 2026 Results and Raises Full Year Guidance
- ❖Oct 28, 10:50 AMnewsvia finnhub
Labcorp Holdings Inc. (LH) Q3 2026 Earnings Call Transcript
Labcorp Holdings Inc. (LH) Q3 2026 Earnings Call October 28, 2026 9:00 AM EDTCompany ParticipantsNickolo RussoAdam Schechter - President, CEO &...
- ❖Oct 28, 9:54 AMnewsvia finnhub
Labcorp Targets Margin Growth, Absorbs Policy Headwinds
Labcorp shares reach a 52-week high after beating Q3 consensus estimates. The company raises fiscal 2026 guidance and expands diagnostic acquisitions.
- ❖Oct 28, 9:47 AMnewsvia finnhub
Can Hims & Hers Stock Fall 30%?
For questions about this article or underlying research, email help@trefis.com.
- ❖Oct 28, 9:24 AMnewsvia finnhub
LH Stock Rises on Q3 Earnings and Revenue Beat, '26 View Up
Labcorp shares rise as Q3 earnings and revenues beat estimates, both segments deliver growth, margins expand and the company raises its 2026 financial outlook.
- ❖Oct 28, 8:47 AMnewsvia finnhub
Labcorp Holdings (NYSE:LH) Posts In-Line Q3 Results and Raises Full-Year Outlook
Labcorp (NYSE:LH) posts in-line Q3 2026 results and raises full-year outlook, sending shares higher premarket despite a slight revenue miss.
- ❖Oct 28, 8:30 AMnewsvia finnhub
SK Hynix, Vertiv Rescue AI Trade As Oil Tops $102 Before Fed: Stock Market Today
Stock market today: SK hynix and Vertiv rally on AI-driven results as oil tops $102 on Iran fears and the 10-year yield tops 5% before the Fed; SMH gains.
- ?Oct 16, 3:20 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
LH is down 2.44% today on news that it is acquiring select BioReference assets from OPKO Health for $722M. Acquirer selloffs on deal announcements are common as the market prices in execution risk, integration costs, and capital deployment concerns — this headline is a plausible catalyst for the move and gives it some fundamental grounding. The macro context (elevated mortgage rates) is not directly relevant to LH as a diagnostics/lab company. With only 25 minutes remaining until the forced close, there is limited runway for further downside to develop, which dampens conviction. However, the deal-related selling pressure tends to persist through the session as institutional holders reassess position sizing, and there is no obvious reversal catalyst visible. The move magnitude (2.44%) is meaningful and suggests real conviction from sellers. Balancing the limited time remaining against sustained deal-related flow, a modest continuation probability is warranted — not a high-conviction setup, but no strong reason to expect a fade either.
- !Oct 16, 3:20 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
LH is down 2.44% today on news that it is acquiring select BioReference assets from OPKO Health for $722M. Acquirer selloffs on deal announcements are common as the market prices in execution risk, integration costs, and capital deployment concerns — this headline is a plausible catalyst for the move and gives it some fundamental grounding. The macro context (elevated mortgage rates) is not directly relevant to LH as a diagnostics/lab company. With only 25 minutes remaining until the forced close, there is limited runway for further downside to develop, which dampens conviction. However, the deal-related selling pressure tends to persist through the session as institutional holders reassess position sizing, and there is no obvious reversal catalyst visible. The move magnitude (2.44%) is meaningful and suggests real conviction from sellers. Balancing the limited time remaining against sustained deal-related flow, a modest continuation probability is warranted — not a high-conviction setup, but no strong reason to expect a fade either.
- ?Oct 6, 1:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- ?Oct 6, 1:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- !Oct 6, 1:20 PMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- !Oct 6, 1:20 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- ?Oct 6, 10:20 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- !Oct 6, 10:20 AMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- ?Oct 6, 10:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- !Oct 6, 10:20 AMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- ?Oct 5, 1:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- !Oct 5, 1:21 PMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- ?Oct 5, 1:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- !Oct 5, 1:21 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- ?Oct 5, 12:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- !Oct 5, 12:20 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- ?Oct 5, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- !Oct 5, 12:20 PMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- ?Oct 5, 11:21 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- !Oct 5, 11:21 AMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- ?Oct 5, 11:21 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- !Oct 5, 11:21 AMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- ?Oct 2, 3:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- !Oct 2, 3:20 PMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- ?Oct 2, 3:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- !Oct 2, 3:20 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- ?Oct 2, 2:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- !Oct 2, 2:20 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- ?Oct 2, 2:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- !Oct 2, 2:20 PMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- ?Oct 2, 1:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- !Oct 2, 1:21 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- ?Oct 2, 1:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- !Oct 2, 1:21 PMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- ?Oct 2, 12:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- !Oct 2, 12:20 PMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- ?Oct 2, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- !Oct 2, 12:20 PMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- ?Oct 2, 11:20 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- ?Oct 2, 11:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- !Oct 2, 11:20 AMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- !Oct 2, 11:20 AMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- ?Oct 2, 10:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- !Oct 2, 10:20 AMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- ?Oct 2, 10:20 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- !Oct 2, 10:20 AMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- ?Oct 2, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- !Oct 2, 7:01 AMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- ?Oct 2, 7:00 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- !Oct 2, 7:00 AMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- ?Oct 1, 4:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- !Oct 1, 4:21 PMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- ?Oct 1, 4:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- !Oct 1, 4:21 PMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- ?Oct 1, 3:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- ?Oct 1, 3:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- ?Oct 1, 2:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- ?Oct 1, 2:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- ?Oct 1, 1:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) is a financially stable, large-cap diagnostics company with no evidence of fundamental deterioration in the recent 8-K filings. However, several headwinds weigh on the rebound thesis: earnings are 25 days away (a meaningful uncertainty premium, -1), options flow is notably bearish with a P/C ratio of 2.52 (-1), the 10Y yield at 5.26% is above 4.5% creating a structural headwind (-1), and the drop of only ~10% (below the 15% threshold) does not qualify as a strong mean-reversion signal. The sector (Health Care) shows only marginal relative strength and slightly negative 30-day performance vs SPY, and there is no insider buying or unusual call activity to offset these negatives. Net signal score is approximately -2 to -3, insufficient to support a buy.
- ?Oct 1, 1:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LH (Labcorp) is a fundamentally sound diagnostics/CRO business with a 10.1% dip from its 30-day high and no visible negative catalyst — no bearish headlines, no SEC filings with adverse metrics, and no insider selling. However, confirmation signals are absent: no insider cluster buys, no unusual call flow (P/C ratio of 2.52 is notably put-heavy, suggesting defensive positioning or mild bearishness from options traders), and no analyst upgrades. Earnings are 25 days away, which sits in the elevated-caution zone and creates binary event risk that limits upside conviction. The macro backdrop is mildly negative for rate-sensitive names given 10Y at 5.26% and T5YIFR 2.0σ above trend, though healthcare (XLV ranked 3rd of 11) shows relative resilience.
- ?Sep 24, 3:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) shows no fundamental deterioration from recent 8-K filings (no guidance cuts, covenant issues, or going-concern language), and the Health Care sector is modestly outperforming on a 30-day basis (+0.82pts vs SPY), suggesting this ~10.4% drop may be sector/macro noise rather than idiosyncratic impairment. However, earnings are 33 days away (2026-10-26), which applies a meaningful headwind penalty, and the macro environment is unfavorable: 10Y yields at 4.96% (above the 4.5% threshold, a negative for the name), today's broad risk-off tape (SPY -0.75%, IEF -1.25%, VXX +2.07%), and 5YIFR elevated 1.7σ above trend. Signal tally: +1 (no fundamental deterioration/clean filing), -1 (earnings in 15-30 day window), -1 (10Y yield >4.5%), -1 (sector outperforming while stock drops idiosyncratically), netting to -2, with no offsetting insider cluster buys or unusual call flow to rescue the thesis. The drop magnitude of 10.4% falls short of the 15% mean-reversion threshold for an additional positive signal.
- ?Sep 24, 3:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] The 11.1% drop appears linked to a CMS (Centers for Medicare & Medicaid Services) policy-related selloff, which the latest analyst headline characterizes as an "excellent opportunity" with a Strong Buy rating — suggesting the market may be overreacting to a regulatory headline rather than a lasting fundamental impairment. Labcorp is a financially durable, diversified diagnostic lab company with stable cash flows, and earnings are 32 days away (non-imminent), reducing binary event risk. The Health Care sector has shown mild relative outperformance over 30 days (+0.83pts vs SPY), suggesting LH's drop is more idiosyncratic and potentially mean-reverting as CMS fears are digested.
- ?Sep 24, 2:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) shows no fundamental deterioration from recent 8-K filings (no guidance cuts, covenant issues, or going-concern language), and the Health Care sector is modestly outperforming on a 30-day basis (+0.82pts vs SPY), suggesting this ~10.4% drop may be sector/macro noise rather than idiosyncratic impairment. However, earnings are 33 days away (2026-10-26), which applies a meaningful headwind penalty, and the macro environment is unfavorable: 10Y yields at 4.96% (above the 4.5% threshold, a negative for the name), today's broad risk-off tape (SPY -0.75%, IEF -1.25%, VXX +2.07%), and 5YIFR elevated 1.7σ above trend. Signal tally: +1 (no fundamental deterioration/clean filing), -1 (earnings in 15-30 day window), -1 (10Y yield >4.5%), -1 (sector outperforming while stock drops idiosyncratically), netting to -2, with no offsetting insider cluster buys or unusual call flow to rescue the thesis. The drop magnitude of 10.4% falls short of the 15% mean-reversion threshold for an additional positive signal.
- ?Sep 24, 2:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] The 11.1% drop appears linked to a CMS (Centers for Medicare & Medicaid Services) policy-related selloff, which the latest analyst headline characterizes as an "excellent opportunity" with a Strong Buy rating — suggesting the market may be overreacting to a regulatory headline rather than a lasting fundamental impairment. Labcorp is a financially durable, diversified diagnostic lab company with stable cash flows, and earnings are 32 days away (non-imminent), reducing binary event risk. The Health Care sector has shown mild relative outperformance over 30 days (+0.83pts vs SPY), suggesting LH's drop is more idiosyncratic and potentially mean-reverting as CMS fears are digested.
- ?Sep 24, 1:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) shows no fundamental deterioration from recent 8-K filings (no guidance cuts, covenant issues, or going-concern language), and the Health Care sector is modestly outperforming on a 30-day basis (+0.82pts vs SPY), suggesting this ~10.4% drop may be sector/macro noise rather than idiosyncratic impairment. However, earnings are 33 days away (2026-10-26), which applies a meaningful headwind penalty, and the macro environment is unfavorable: 10Y yields at 4.96% (above the 4.5% threshold, a negative for the name), today's broad risk-off tape (SPY -0.75%, IEF -1.25%, VXX +2.07%), and 5YIFR elevated 1.7σ above trend. Signal tally: +1 (no fundamental deterioration/clean filing), -1 (earnings in 15-30 day window), -1 (10Y yield >4.5%), -1 (sector outperforming while stock drops idiosyncratically), netting to -2, with no offsetting insider cluster buys or unusual call flow to rescue the thesis. The drop magnitude of 10.4% falls short of the 15% mean-reversion threshold for an additional positive signal.
- ?Sep 24, 1:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] The 11.1% drop appears linked to a CMS (Centers for Medicare & Medicaid Services) policy-related selloff, which the latest analyst headline characterizes as an "excellent opportunity" with a Strong Buy rating — suggesting the market may be overreacting to a regulatory headline rather than a lasting fundamental impairment. Labcorp is a financially durable, diversified diagnostic lab company with stable cash flows, and earnings are 32 days away (non-imminent), reducing binary event risk. The Health Care sector has shown mild relative outperformance over 30 days (+0.83pts vs SPY), suggesting LH's drop is more idiosyncratic and potentially mean-reverting as CMS fears are digested.
- ?Sep 24, 12:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] The 11.1% drop appears linked to a CMS (Centers for Medicare & Medicaid Services) policy-related selloff, which the latest analyst headline characterizes as an "excellent opportunity" with a Strong Buy rating — suggesting the market may be overreacting to a regulatory headline rather than a lasting fundamental impairment. Labcorp is a financially durable, diversified diagnostic lab company with stable cash flows, and earnings are 32 days away (non-imminent), reducing binary event risk. The Health Care sector has shown mild relative outperformance over 30 days (+0.83pts vs SPY), suggesting LH's drop is more idiosyncratic and potentially mean-reverting as CMS fears are digested.
- ?Sep 24, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) shows no fundamental deterioration from recent 8-K filings (no guidance cuts, covenant issues, or going-concern language), and the Health Care sector is modestly outperforming on a 30-day basis (+0.82pts vs SPY), suggesting this ~10.4% drop may be sector/macro noise rather than idiosyncratic impairment. However, earnings are 33 days away (2026-10-26), which applies a meaningful headwind penalty, and the macro environment is unfavorable: 10Y yields at 4.96% (above the 4.5% threshold, a negative for the name), today's broad risk-off tape (SPY -0.75%, IEF -1.25%, VXX +2.07%), and 5YIFR elevated 1.7σ above trend. Signal tally: +1 (no fundamental deterioration/clean filing), -1 (earnings in 15-30 day window), -1 (10Y yield >4.5%), -1 (sector outperforming while stock drops idiosyncratically), netting to -2, with no offsetting insider cluster buys or unusual call flow to rescue the thesis. The drop magnitude of 10.4% falls short of the 15% mean-reversion threshold for an additional positive signal.
- ?Sep 24, 11:22 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) shows no fundamental deterioration from recent 8-K filings (no guidance cuts, covenant issues, or going-concern language), and the Health Care sector is modestly outperforming on a 30-day basis (+0.82pts vs SPY), suggesting this ~10.4% drop may be sector/macro noise rather than idiosyncratic impairment. However, earnings are 33 days away (2026-10-26), which applies a meaningful headwind penalty, and the macro environment is unfavorable: 10Y yields at 4.96% (above the 4.5% threshold, a negative for the name), today's broad risk-off tape (SPY -0.75%, IEF -1.25%, VXX +2.07%), and 5YIFR elevated 1.7σ above trend. Signal tally: +1 (no fundamental deterioration/clean filing), -1 (earnings in 15-30 day window), -1 (10Y yield >4.5%), -1 (sector outperforming while stock drops idiosyncratically), netting to -2, with no offsetting insider cluster buys or unusual call flow to rescue the thesis. The drop magnitude of 10.4% falls short of the 15% mean-reversion threshold for an additional positive signal.
- ?Sep 24, 11:21 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] The 11.1% drop appears linked to a CMS (Centers for Medicare & Medicaid Services) policy-related selloff, which the latest analyst headline characterizes as an "excellent opportunity" with a Strong Buy rating — suggesting the market may be overreacting to a regulatory headline rather than a lasting fundamental impairment. Labcorp is a financially durable, diversified diagnostic lab company with stable cash flows, and earnings are 32 days away (non-imminent), reducing binary event risk. The Health Care sector has shown mild relative outperformance over 30 days (+0.83pts vs SPY), suggesting LH's drop is more idiosyncratic and potentially mean-reverting as CMS fears are digested.
- ✓Sep 24, 7:04 AMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
The 11.1% drop appears linked to a CMS (Centers for Medicare & Medicaid Services) policy-related selloff, which the latest analyst headline characterizes as an "excellent opportunity" with a Strong Buy rating — suggesting the market may be overreacting to a regulatory headline rather than a lasting fundamental impairment. Labcorp is a financially durable, diversified diagnostic lab company with stable cash flows, and earnings are 32 days away (non-imminent), reducing binary event risk. The Health Care sector has shown mild relative outperformance over 30 days (+0.83pts vs SPY), suggesting LH's drop is more idiosyncratic and potentially mean-reverting as CMS fears are digested.
- ?Sep 24, 7:00 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
LH (Labcorp) shows no fundamental deterioration from recent 8-K filings (no guidance cuts, covenant issues, or going-concern language), and the Health Care sector is modestly outperforming on a 30-day basis (+0.82pts vs SPY), suggesting this ~10.4% drop may be sector/macro noise rather than idiosyncratic impairment. However, earnings are 33 days away (2026-10-26), which applies a meaningful headwind penalty, and the macro environment is unfavorable: 10Y yields at 4.96% (above the 4.5% threshold, a negative for the name), today's broad risk-off tape (SPY -0.75%, IEF -1.25%, VXX +2.07%), and 5YIFR elevated 1.7σ above trend. Signal tally: +1 (no fundamental deterioration/clean filing), -1 (earnings in 15-30 day window), -1 (10Y yield >4.5%), -1 (sector outperforming while stock drops idiosyncratically), netting to -2, with no offsetting insider cluster buys or unusual call flow to rescue the thesis. The drop magnitude of 10.4% falls short of the 15% mean-reversion threshold for an additional positive signal.
- ✓Sep 23, 6:02 PMdecisionacted
Agent 4 — Dip Buyer (Frozen) — decide: buy
LH (Labcorp) is a well-established diagnostics and clinical research company with a diversified business model and historically stable cash flows, suggesting no fundamental deterioration underpins this ~11% drawdown from its 30-day high. The available 8-K filings carry no financial metrics that signal guidance cuts, earnings misses, or accounting concerns, and there are no negative news headlines in the 30-day window to explain company-specific selling pressure. The macro headwind is a modestly elevated 5-year forward inflation rate (T5YIFR at 1.7σ above trend), which could weigh on rate-sensitive equities broadly, but an 11% pullback in a sound, defensive-leaning healthcare name during this backdrop looks more like sector rotation than fundamental impairment — a setup that historically mean-reverts.
- ▢Sep 22, 8:00 PMjournal
Agent 4 — Dip Buyer (Frozen) opened long 3 @ $303.98
- ▢Jul 22, 8:00 PMjournal
Agent 7 — Day Trader opened long 9 @ $295.99
- ▣Jul 22, 8:00 PMjournalstop
Agent 7 — Day Trader closed long 9 @ $291.30 (-$42.21)
Long stop: close $291.30 ≤ stop $291.55